C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill in vitro and in vivo in Acute Myeloid Leukemia and Lymphomas

Authors

Yuki Nishida MD, PhD, The University of Texas MD Anderson Cancer Center
Darah A. Scruggs, The University of Texas MD Anderson Cancer Center
Edward Ayoub PhD, The University of Texas MD Anderson Cancer Center
Tallie Patsilevas, The University of Texas MD Anderson Cancer Center
Lauren Ostermann, The University of Texas MD Anderson Cancer Center
Vivian R. Ruvolo, The University of Texas MD Anderson Cancer Center
Po Yee Mak, The University of Texas MD Anderson Cancer Center
Bing Z. Carter, The University of Texas MD Anderson Cancer Center
Steffen Boettcher, The University of Zurich
Abhishek Maiti, The University of Texas MD Anderson Cancer Center
Qianxiang Zhou, Kintor Pharmaceutical Ltd.
Zhaohui Yang, Kintor Pharmaceutical Ltd.
Honghua Yan, Kintor Pharmaceutical Ltd.
Liandong Ma, Kintor Pharmaceutical Ltd.
Michael Andreeff MD, PhD, The University of Texas MD Anderson Cancer Center

Files

Abstract

View full abstract

DOI

https://doi.org/10.52519/00071

Publication Date

2022

Keywords

Targeting oncoproteins

Department

Leukemia

Research Category

Other

Recommended Citation

Nishida, Yuki MD, PhD; Scruggs, Darah A.; Ayoub, Edward PhD; Patsilevas, Tallie; Ostermann, Lauren; Ruvolo, Vivian R.; Mak, Po Yee; Carter, Bing Z.; Boettcher, Steffen; Maiti, Abhishek; Zhou, Qianxiang; Yang, Zhaohui; Yan, Honghua; Ma, Liandong; and Andreeff, Michael MD, PhD, "C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill in vitro and in vivo in Acute Myeloid Leukemia and Lymphomas" (2022). Leading Edge of Cancer Research Symposium. 21.
doi:https://doi.org/10.52519/00071